Opus Genetics Inc
Company Profile
Business description
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Contact
8 Davis Drive
Suite 220
DurhamNC27709
USAT: +1 984 884-6030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
18
Stocks News & Analysis
stocks
After earnings, is Uber stock a buy, a sell, or fairly valued?
stocks
The largest share trading on the ASX remains materially overvalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,110.80 | 6.60 | -0.07% |
| CAC 40 | 8,156.23 | 0.00 | 0.00% |
| DAX 40 | 24,088.06 | 128.07 | 0.53% |
| Dow JONES (US) | 47,927.96 | 559.33 | 1.18% |
| FTSE 100 | 9,899.60 | 112.45 | 1.15% |
| HKSE | 26,696.41 | 47.35 | 0.18% |
| NASDAQ | 23,468.30 | 58.87 | -0.25% |
| Nikkei 225 | 50,887.76 | 44.83 | 0.09% |
| NZX 50 Index | 13,655.62 | 51.07 | 0.38% |
| S&P 500 | 6,846.61 | 14.18 | 0.21% |
| S&P/ASX 200 | 8,830.30 | 5.70 | -0.06% |
| SSE Composite Index | 4,002.76 | 15.84 | -0.39% |